News Updates
Scope

Wed, May 27, 2026

1 updates
AVIR
7:00 AM

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting Antiviral for the Treatment of Hepatitis E Virus BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc.

Presentation / Abstract • Phase 1EASL abstract release Thu, May 28, 2026, 8:30 AM CESTateapharma.com

Wed, May 13, 2026

1 updates
AVIR
7:00 AM

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been

Presentation / AbstractEASL abstract release Wed, May 13, 2026, 8:00 AM CETateapharma.com

Tue, May 12, 2026

1 updates

Tue, May 5, 2026

1 updates

Thu, Mar 5, 2026

1 updates